➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
AstraZeneca
Colorcon
Harvard Business School
Medtronic

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,938,798

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,938,798 protect, and when does it expire?

Patent 6,938,798 protects BAQSIMI and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 6,938,798
Title: Fluid or powdery product dispensing device
Abstract:A device for dispensing a substance in fluid or powder form, the device having a dispensing outlet (10), an air blaster (20) for generating a blast of air when the device is actuated, and at least one reservoir (30) containing a single dose of substance. The reservoir (30) an air inlet (31) connected to the air blaster (20), and a substance outlet (32) connected to the dispensing orifice (10), the air inlet (31) being provided with a substance retaining member (40) for retaining the substance in the reservoir (30) until it is dispensed, and the substance outlet (32) being closed off by a closure element (50). The dispenser device is configured such that the closure element (50) is a spherical element, such as a ball, force fitted into the substance outlet (32) of the reservoir (30). The device further has a mechanical opening system (60, 70, 80) co-operating with the closure element (50) for ejecting it mechanically from its closure position when the device is actuated.
Inventor(s): Stradella; Giuseppe (Camogli, IT)
Assignee: TEBRO S.A. (Luxembourg, LU)
Application Number:10/416,873
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 6,938,798

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co BAQSIMI glucagon POWDER;NASAL 210134-001 Jul 24, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,938,798

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 15998Dec 8, 2000
PCT Information
PCT FiledDecember 04, 2001PCT Application Number:PCT/EP01/15408
PCT Publication Date:June 13, 2002PCT Publication Number: WO02/45866

International Family Members for US Patent 6,938,798

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 3849402   Start Trial
China 1240482   Start Trial
China 1494461   Start Trial
Germany 60141345   Start Trial
European Patent Office 1339501   Start Trial
France 2817847   Start Trial
Japan 2004532717   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Mallinckrodt
Johnson and Johnson
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.